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ABSTRACT 
 
Objective: Although available evidence is modest, exercise could be beneficial in reducing 
behavioural and psychological symptoms of dementia. We aim to evaluate the cost-
effectiveness of a dyadic exercise regimen for individuals with dementia and their main 
carer as therapy for behavioural and psychological symptoms of dementia. 
  
Methods: Cost-effectiveness analysis within a two-arm, pragmatic, randomised, controlled, 
single-blind, parallel-group trial of a dyadic exercise regimen (individually tailored, for 20-30 
minutes at least five times per week). The study randomised 131 community-dwelling 
individuals with dementia and clinically significant behavioural and psychological symptoms 
with a carer willing and able to participate in the exercise regimen; 52 dyads provided 
sufficient cost data for analyses.  
 
Results: Mean intervention cost was £284 per dyad. For the sub-sample of 52 dyads, the 
intervention group had significantly higher mean cost from a societal perspective (mean 
difference £2728.60, p=0.05), but costs were not significantly different from a health and 
social care perspective. The exercise intervention was more cost-effective than treatment as 
usual from both societal and health and social care perspectives for the measure of 
behavioural and psychological symptoms (Neuro Psychiatric Inventory). It does not appear 
cost-effective in terms of cost per quality-adjusted life year gain.  
 
Conclusions 
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The exercise intervention has the potential to be seen as cost-effective when considering 
behavioural and psychological symptoms, but did not appear cost-effective when 
considering Quality Adjusted Life Year gains. 
 
 
INTRODUCTION 
 
Exercise has been suggested as a potential risk-reduction factor for dementia (Norton et al., 
2014; Ngandu et al., 2015), and has also been suggested as a suitable intervention to 
address behavioural and psychological symptoms of dementia (BPSD) for people with 
established dementia (Brodaty and Arasaratnam, 2012). The EVIDEM-E trial investigated the 
effect of an individually tailored walking regimen for 131 dyads (pairs of people with 
dementia and their carer) on BPSD experienced by these individuals (Lowery et al., 2014). 
The aim of this paper is to estimate the cost-effectiveness of this exercise intervention.  
 
Non-pharmacological approaches are often effective, and may also be preferable 
alternatives to pharmacological interventions for BPSD. Exercise is potentially a particularly 
attractive option given its simplicity and potential positive spill-over effects when 
considering physical health. Nevertheless, it is important to consider the cost-effectiveness 
of any intervention, in order to ensure resources are being used efficiently, and that 
interventions are financially viable. This is particularly important for interventions aimed at 
assisting people with dementia given the context of an ageing population, which will place 
much greater future demands on health and social care systems that are already stretched 
(Prince et al., 2014).   
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METHODS  
 
Intervention design 
 
The intervention delivered physical exercise in the form of 12-week individually tailored 
walking programme lasting for 20-30 minutes daily, designed to become progressively more 
intensive. Sessions were facilitated by a registered exercise professional qualified in 
instructing physical activity and exercise (National Vocational Qualification Level 3) and 
delivered to individuals within the intervention group in and around their own home. The 
exercise therapist progressively withdrew support over the first six weeks (and provided no 
support over weeks 7-12), with the expectation that the dyad would perform the exercise 
regimen regularly and independently at least five times per week. All participants were 
asked to record their daily activities throughout the 12 weeks of participation using a diary 
designed for the study. The intervention group diary contained an additional visual analogue 
scale, the Rating of Perceived Exertion (RPE) (Borg, 1982). Participants were encouraged to 
extend (or reduce in some circumstance) the level of intensity to between 12 and 14 on the 
RPE scale.  
 
Participants 
 
Participants were community-dwelling, and lived in inner city, urban and semi-rural areas in 
and around London. Recruitment was performed from the North Thames Dementias and 
Neuro-Degenerative Diseases Research Network’s dementia research register (NTDEMREG) 
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(Iliffe et al., 2011), through self-referral; through primary clinical services or through 
specialist mental health services (e.g., memory assessment and community mental health).  
 
Participants were eligible for inclusion if they had a clinical diagnosis of dementia (defined 
by ICD-10 Diagnostic Criteria for Research (DCR-10) (1992)), and one or more significant 
BPSD symptom defined by a Neuropsychiatric Inventory (NPI; minimum score of frequency = 
2, and severity = 2) (Cummings et al., 1994), excluding hallucinations or delusions.  To be 
eligible, participants also required a carer who was willing and able to participate with the 
exercise regimen, and to complete a falls risk assessment. 
 
A full description of participants can be found in (Lowery et al., 2014).  
 
Randomisation 
 
Study participants were assigned randomly to one of two trial arms. The intervention group 
received the exercise regimen in addition to treatment as usual (TAU). The control group 
received only treatment as usual. Individuals were allocated to these groups in a 1:1 ratio 
using a computer algorithm. Trial participants, carers, the participant’s GP and the therapist 
were not blinded to treatment allocation; however, other individuals involved with the trail 
were blinded until analyses were completed. A full discussion of randomisation within the 
trial can be found in the published trial protocol (Cerga-Pashoja et al., 2010). 
 
Measures of outcomes 
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All outcomes were measured at baseline, at 6 weeks and 12 weeks (Lowery et al., 2014). For 
the effectiveness analyses (Lowery et al., 2014), the primary outcome measure was a 
between-group difference of proportions of people with a reduction of three or more points 
on the composite NPI score (Cummings et al., 1994) at 12 weeks, which was chosen as a 
clinically significant change in BPSD symptoms. Secondary outcome measures were: mean 
difference in scores at 12 weeks on the NPI, General Health Questionnaire (GHQ) (Goldberg, 
1972), DemQOL-Proxy (DEMQOL) (Smith et al., 2007), and Zarit Caregiver Burden Inventory 
(ZBI) (Bedard et al., 2001). 
 
For the cost-effectiveness analyses, the primary outcome measure was mean difference in 
NPI score. Secondary outcome measures were mean difference in ZBI, GHQ and DEMQOL-
proxy score, as well as QALYs calculated using these DEMQOL-proxy scores (Mulhern et al., 
2013).    
 
Resource use and cost measures 
 
Data on care and support service utilisation were collected using an adapted version of the 
Client Service Receipt Inventory (CSRI) (Beecham and Knapp, 2001), completed by the carer. 
The CSRI was completed at baseline and 12 weeks, and on each occasion asked about 
service receipt retrospectively over the previous 3 months. Data were collected on health 
and social care services (hospital services, day services, and community health and social 
care services), equipment and adaptations, medication and unpaid carer inputs.  
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Whenever possible, unit costs were taken from the Personal Social Services Research Unit 
(PSSRU) compendium for 2011 (Curtis, 2011), and reflect long-run marginal opportunity 
costs. The British National Formulary database was consulted with regards to costs for 
medication. Where costs for equipment and adaptations to home were not available in the 
PSSRU compendium they were estimated from market sources. Although most unit costs 
were found at 2011 prices, where this was not possible, available figures were adjusted to 
2011 prices. Where services or equipment would continue to provide a benefit for more 
than one year (e.g. adaptations to home), costs were annuitised using the HM Treasury 
recommended annual discount rate of 3.5%. Unpaid care costs were estimated using an 
hourly rate equal to the National Minimum Wage, under the assumption that this was the 
potential opportunity cost for the unpaid carers.  
 
Cost-effectiveness analyses 
 
The cost-effectiveness analyses were conducted from two perspectives: the health and 
social care (HSC) perspective and societal perspective. The main difference between these 
perspectives is that the latter includes costs for unpaid carer time. The primary cost-
effectiveness analyses from each perspective compared the exercise regimen and control 
groups on mean cost and mean difference in composite NPI score. Secondary cost-
effectiveness analyses compared the groups on cost and each of the following outcomes in 
turn: the ZARIT caregiver burden inventory (ZBI), DEMQOL-Proxy, General Health 
Questionnaire (GHQ) and a measure of quality-adjusted life years (QALYs) generated from 
DEMQOL-Proxy scores. Scores on the outcome variables for which lower scores show better 
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outcomes have been reversed in order to have a more intuitive interpretation for the 
economic analysis.  
If the exercise regime is more effective (has superior outcomes) and less costly than usual 
care, then it is said to strongly dominate the control intervention. If the exercise regimen 
has worse outcomes and higher costs than control, then it is said to be strongly dominated. 
In other circumstances the decision about whether or not to choose one intervention over 
the other is not straightforward, and the decision-maker must judge the differences in 
outcomes and costs before choosing one intervention over the other. The value or weight 
attached to differences in outcomes will play a part in making this decision. In such cases, 
we would calculate the incremental cost-effectiveness ratio (ICER): 
ICER= ΔC /ΔE, 
ΔC is mean incremental cost – the difference between the exercise regimen and control – 
and ΔE is the corresponding mean incremental outcome. The ICER aids the decision making 
process by displaying the cost (or cost savings) per unit change in the outcome considered.    
Each ICER was estimated using the SUR (Seemingly Unrelated Regression) model within 
STATA (Stata Corp., 2013). Each cost and outcome measure in turn was regressed on 
treatment allocation, controlling respectively for cost and that same outcome measure at 
baseline. Regression models were bootstrapped with 1,000 replications in order to address 
potential skewness within the data. Multiple imputation (using ten imputed datasets) was 
employed to deal with missing values in some outcomes and covariates. 
The formula NB=λ*ΔE- ΔC was used to calculate net benefits (NB), which in addition to using 
mean cost and outcome differences, used a range of hypothetical values of willingness-to-
pay (λ)  for an additional unit on a given outcome measure. Cost-effectiveness acceptability 
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curves (CEACs) were then plotted for the primary outcome (NPI) using the net-benefit 
values calculated for each value of willingness-to-pay within the range of £0 to £10,000. This 
showed the probability of the exercise regimen being cost-effective over other willingness-
to-pay values considered.  
Economic analysis was conducted using STATA 13. 
 
 
Sensitivity analyses 
 
As part of a sensitivity analysis, we controlled additionally for participant age at baseline, 
gender, ethnicity, marital status, education level, whether living in a care home, MMSE 
score at baseline, carer’s age and gender when performing regression analyses on cost and 
outcome measures when estimating ICERs.  
 
Results 
 
Sample characteristics 
 
One hundred and thirty-one participant dyads were randomized to the intervention and 
control groups, and 113 (89%) completed the trial. The two groups were similar with respect 
to mean age, type of dementia and other characteristics including outcome scores. 
Descriptive statistics for the baseline demographic and the outcomes are presented in 
(Lowery et al., 2014). 
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Completed CSRIs were received from 74 dyads at baseline and 67 at 12-week follow-up. 
Depending on the outcome variable however, the matching sample for the economic 
analysis varied from between 49 and 52 dyads because of missing data on some measures. 
Multiple imputation techniques with chained equations, were used to estimate missing 
outcome and socio-demographic data (Rubin, 1987), yielding a subsample of 52 dyads (22 
within the control group, 30 in the intervention group) which could be analysed. Hereafter, 
our findings on service use, costs and cost-effectiveness are based on the 52 dyads in this 
sub-sample, which is slightly less than half of the sample available for the main outcome 
analysis (116 dyads).  
 
We tested whether the economic analysis subsample was different from the original sample 
of 131 dyads by using the Wilcoxon rank-sum test for continuous variables and the Fisher 
Exact Test (or the Pearson Chi-2 test when appropriate) for binary variables, as shown in 
table 1. We found no significant differences between the ‘economic subsample’ and the rest 
of the sample at confidence level of 95% (with the smallest p-value of 0.07 associated with 
the ‘primary education or less’ variable). Looking at the differences between the 
intervention and control groups within the ‘economic subsample’, again no significant 
differences were found, with the smallest p-value of 0.07 for MMSE score at baseline.  
------- 
Table 1 
------- 
Service receipt 
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Service utilisation rates are presented in table 2. At baseline, there were no significant 
differences in service use by treatment group. At 12-weeks follow-up, overall proportions 
remained fairly similar. The two groups diverged with respect to utilisation of hospital 
services, with the percentage utilising these in the control group increasing (to 73%) 
whereas the proportion using these in the intervention group decreased (to 47%). However, 
as was the case with every other service use category at follow-up and at baseline, the 
difference between trial arms was not significant at the 5% level (p=0.09). 
------- 
Table 2 
------- 
 
Costs 
 
Average intervention cost per dyad 
Total intervention cost was calculated by multiplying unit cost per visit (£60) or unit cost per 
phone call (£10) by number of contacts between the exercise professional and each dyad. 
Mean intervention cost per dyad was £284 (range £190 to £320). 
 
Cost analyses  
 
Table 3 displays baseline and 12-week follow-up service use costs. At baseline, the summary 
statistics suggest that a sizeable proportion of total health and social care (HSC) service 
costs are related to use of accommodation services. At baseline there was no significant 
difference between the groups in terms of mean accommodation service costs. Apart from 
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accommodation, hospital and community services displayed the highest aggregate costs. 
Total HSC costs were £3,205 and £2,655 for the intervention and control groups 
respectively; the difference was not significant. There was also no significant difference 
between the groups in terms of mean societal cost (control group, £9,218; intervention 
group, £11,017) inclusive of the provision of unpaid care (control, £6,563; intervention, 
£7,812). 
 
At follow-up, there was a significant difference in the cost of medications between the 
control (mean £246.30) and the intervention group (£285.20) (p=0.04), but we are unclear 
why this occurred. There was no significant between group difference in the cost of unpaid 
care. Total societal costs, including intervention and provision of unpaid care, was £10,533 
for the intervention group versus £7,805 for the control group. After adjustment for 
baseline covariates this difference was not significant. 
------- 
Table 3 
------- 
 
Outcomes 
 
Table 3 also displays the differences in outcomes between the intervention and the control 
groups at both time points. The economic subsample showed a significant between-group 
difference in scores for the General Health Questionnaire (GHQ) at 12 weeks, with the 
intervention group showing better scores on average (18.0 vs 23.2) than the control group. 
It should be noted however that prior to multiple imputations, data on GHQ scores were 
13 
 
recorded on a slightly reduced economic subsample of 49 respondents, and this difference 
was not found to be significant within the entire sample (Lowery et al., 2014). No other 
significant between group outcome differences were found, in particular at baseline, 
meaning that the effect of randomisation persisted when considering the economic 
subsample as opposed to the entire sample. 
 
 
Cost-effectiveness 
 
In Table 4 we report the incremental costs and incremental effects for the primary and 
secondary outcome measures.  
 
From a HSC perspective, we found that incremental costs were negative, i.e. the 
intervention group had lower costs than the control group (by approximately £170) and 
incremental effects were positive, i.e. the intervention group achieved better outcomes. 
Although none of these differences was significant at the 5% level, the results suggest that 
the exercise regimen dominated treatment as usual. To examine that possibility further, 
given that there were wide confidence intervals on the incremental differences, we plotted 
the CEACs for the primary and secondary outcomes. The CEACs for the primary outcome 
(NPI) are shown in Figure 1. From a HSC perspective (the dashed line in Figure 1), the CEAC 
suggests that, at a willingness-to-pay of £500 per incremental improvement in outcome (i.e. 
per 1-point difference in NPI score), the exercise regimen is cost-effective with a probability 
higher than 80%.  
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From a societal perspective, the ICER was £421 per incremental difference in NPI score. If a 
reduction of at least three points in the NPI score can be considered clinically meaningful in 
this case (it is suggested that this may vary: http://npitest.net/faqs.html), then this result 
suggests that the cost of achieving a meaningful improvement is £1,263. Whether this 
would be seen as cost-effective is unclear, since there have not been discussions of cost-
effectiveness thresholds for this outcome measure; as ever, it would be for decision-makers 
to make the judgement.  
 
With respect to secondary outcomes from a societal perspective, the ICERs using DEMQOL-
proxy and GHQ as outcome measures were £580 and £392, respectively. With ZBI as the 
outcome measure, the ICER was £1,055. Finally, the ICER for QALYs calculated using 
DEMQOL-proxy scores and societal weights was large, at £286,440.   
------- 
Table 4 
------- 
------- 
Figure 1 
------- 
 
 
Sensitivity analyses 
 
Table 5 presents results for a sensitivity analysis that, in addition to baseline costs and 
baseline outcomes, also controlled for participant age at baseline, gender, ethnicity, marital 
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status, education level, whether living in a care-home, MMSE score at baseline, carer age 
and gender. This analysis provides results which are consistent with the main analysis; in 
particular, for the primary outcome measure of change in NPI score, the ICER calculated was 
equivalent to that of the main analysis.  
------- 
Table 5 
------- 
 
 
 
Discussion 
 
Summary of findings 
 
Some of the authors of this paper previously reported on a randomized, controlled, single-
blind, parallel-group trial in which no evidence was found to support the hypothesis that 
exercise tailored to participant-carer dyads would be clinically effective for the amelioration 
of behavioural and psychological symptoms in dementia (BPSD) (Lowery et al., 2014).  
 
In this paper we reported cost data and cost-effectiveness analyses for a subsample of 
people in that trial. Mean costs for the group following the exercise regimen were not 
significantly different over 12 weeks from costs for the control group receiving treatment as 
usual. This result was found whether a societal or health and social care (HSC) perspective 
was adopted.  
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With respect to differences in outcomes, a significant difference in GHQ score was 
discovered at 12 weeks in the economic subsample, but not in the full sample (Lowery et al., 
2014). The subsample also did not exhibit a significantly different ZBI score at 12 weeks, 
whereas this difference was significant (p=0.01) for the full sample.   
  
Although differences in outcomes and costs were not statistically significant, the cost-
effectiveness acceptability curves (from both HSC and societal perspectives) suggest a high 
probability of cost-effectiveness at values of willingness to pay for one-point improvements 
on the NPI as low as £1000. If a three-point NPI difference can be considered clinically 
meaningful (with suggestions that this varies: http://npitest.net/faqs.html), then decision-
makers (such as commissioners) would need to be prepared to pay at least £3000 for an 
estimated 68% probability of cost-effectiveness (from a societal perspective) and an 
estimated 82% probability of cost-effectiveness (health and social care perspective), 
interpreted as the cost of achieving a clinically meaningful improvement. There is no 
established cost-effectiveness benchmark for NPI with which to compare these estimates in 
the way that there is for QALYs (e.g. stemming from the threshold recommended by 
National Institute for Health and Care Excellence (NICE) in England and Wales). But even 
with cost-effectiveness measured in terms of cost per QALY, whether an intervention is 
cost-effective still comes down to a judgement by the decision-maker as to the ‘worth’ of an 
outcome difference. By this same token, our estimated mean cost per QALY looks high 
relative to the £30,000 upper threshold generally associated with cost-effectiveness 
judgements by NICE. The sensitivity analysis (adjusting for baseline socio-demographic 
variables) generated findings consistent with the main analyses.     
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Comparison with similar studies 
 
Many clinical studies have investigated whether physical exercise is linked to a reduction in 
dementia risk, with the meta-analysis by Hamer et al. (2009) concluding that physical 
exercise is a protective factor for older people against Alzheimer’s disease and other 
dementias. Other systematic reviews of epidemiological studies draw similar conclusions 
(Sofi et al., 2011; Taxeira, 2012). More recent meta-analyses demonstrate a positive impact 
of physical exercise on Alzheimer’s disease risk-reduction (Beydoun et al., 2014). The link 
between exercise and vascular dementia is less clear; meta-analysis by (Aarsland et al., 
2010) found high heterogeneity between studies and the presence of publication bias. 
While there have been a number of studies of the effectiveness of exercise in reducing 
decline in cognitive functioning, to our knowledge there has been no examination of its 
cost-effectiveness (Knapp et al., 2013). 
 
Strengths and limitations of the economic evaluation 
 
The economic evaluation adopted a health and social care perspective for some analyses, 
and a societal perspective for others, ensuring that unpaid carer inputs were not 
overlooked, and to provide relevant results for a greater range of stakeholders. A range of 
outcome measures were examined, including QALYs generated from a dementia-specific 
measure. A limitation of the economic analyses was the sample size, which was  55% lower 
than the sample for the main outcomes analysis because service use data were not available 
for each participant. Even though the subsample for whom we had cost data was not 
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significantly different from the larger sample recruited into the trial, this loss of statistical 
power limits the conclusions that can be drawn. Some of the observed cost differences may 
have reached statistical significance with a larger sample. Another possible limitation is that 
only 85% of study participants provided information about support received from unpaid 
carers, yet we know that all sample members had a carer. It is notoriously difficult to 
estimate accurately the amount of time an unpaid carer spends with someone with 
dementia, which can have an impact on the cost estimated.      
 
 
Implications for policy and practice 
 
This trial demonstrated that regular simple exercise such as walking does not appear to be 
effective with respect to reducing the behavioural and psychological symptoms of dementia, 
it does appear to help reduce carer burden however (Lowery et al., 2014). Our cost-
effectiveness analyses demonstrate that the regular walking regimen would be likely to be 
seen as cost-effective when focusing on NPI as the outcome of interest, but not when 
looking at other outcome measures, for example QALYs. 
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Table 1:  Economic analyses subsample descriptive statistics 
Variable 
Treatment group 
Control  vs. 
Intervention 
( economic 
subsample) 
Economic 
subsample  
vs. rest of 
the 
sample Control Intervention Total 
  
n 
Mean ± S.D. 
/Cases (%) n 
Mean ± S.D. 
/Cases (%) n 
Mean ± S.D. 
/Cases (%) 
Wilcoxon / 
Chi2 test  
p-value  
Wilcoxon 
/ Chi2 test  
p-value 
Age 22 78.4 ± 9.07 30 78.6 ± 7.6 52 78.5 ± 8.2 0.66 0.91 
Carer's age 19 62.2 ± 17.11 25 63.6 ± 16.4 44 63.0 ± 16.5 0.88 0.96 
MMSE 22 17.5 ± 8.17 30 13.6 ± 7.4 52 15.3 ± 7.9 0.07 0.58 
Gender: female 22 13 (59.1) 30 16 (53.3) 52 29 (55.8) 0.78 0.89 
Carer's gender: 
female 
22 15 (68.2) 30 20 (66.7) 52 35 (67.3) 1.00 0.90 
Ethnicity: white 22 18 (81.8) 30 27 (90.0) 52 45 (86.5) 0.44 0.18 
Married or in a 
civil partnership 
22 15 (68.2) 30 22 (73.3) 52 37 (71.2) 0.76 0.62 
Living alone 22 7 (31.8) 30 8 (26.7) 52 15 (28.8) 0.76 0.66 
Paid carer 22 1 (4.5) 30 2 (6.7) 52 3 (5.8) 1.00 1.00 
Living in a care-
home 
22 2 (9.1) 30 4 (13.3) 52 6 (11.5) 1.00 0.98 
Primary 
education or 
less 
21 1 (4.8) 28 1 (3.6) 52 2 (3.8) 1.00 0.07 
Further 
education 
21 2 (9.5) 28 5 (17.9) 52 7 (13.5) 0.68 0.18 
Dementia 
severity: mild 
22 11 (50.0) 28 8 (28.6) 50 19 (38.0) 0.15 0.67 
Dementia 
severity: 
moderate 
22 7 (31.8) 28 10 (35.7) 50 17 (34.0) 1.00 0.78 
Dementia 
severity: marked 
22 4 (18.2) 28 10 (35.7) 50 14 (28.0) 0.22 0.86 
Note: Wilcoxon test was performed for continuous variables (age, MMSE, etc.), while Chi2 test was performed for categorical 
variables (gender, ethnicity, marital status, etc.). 
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Table 2:  Economic analyses subsample service utilisation patterns  
Variable 
Treatment group – number and percentage using services Fisher Exact Test 
Control Intervention Total p-value 
Pre-baseline (3 months)                
Res. Care/ Accommodation 2 9% 4 13% 6 12% 1.00 
Hospital services 14 64% 16 53% 30 58% 0.57 
Community services 14 64% 23 77% 37 71% 0.36 
Equipment and adaptations 12 55% 20 67% 32 62% 0.40 
Day services 8 36% 13 43% 21 40% 0.78 
Medications 22 100% 29 97% 51 98% 1.00 
Unpaid care 19 86% 24 80% 43 83% 0.72 
N 22 100% 30 100% 52 100%   
Follow-up (1-3 months)               
Res. Care / Accommodation 1 5% 3 10% 4 8% 0.63 
Hospital services 16 73% 14 47% 30 58% 0.09 
Community services 12 55% 21 70% 33 63% 0.38 
Equipment and adaptations 12 55% 14 47% 26 50% 0.78 
Day services 10 45% 12 40% 22 42% 0.78 
Medications 22 100% 29 97% 51 98% 1.00 
Unpaid care 18 82% 26 87% 44 85% 0.71 
N 22 100% 30 100% 52 100%   
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Table 3:  Costs (over three months) incurred by the economic analyses subsample  
Variable 
Control (N=22) Intervention (N=30) Total (N=52) 
Bootstrapped t-
test 
Mean 
Std. 
Dev. Min Max Mean 
Std. 
Dev. Min Max Mean 
Std. 
Dev. Min Max Adjusted p-value 
Pre-baseline costs (£)              
Accommodation 951.7 3,080.3 0 10,468 1,300.9 3,478.1 0 13,182 1,153.2 3,288.8 0 13,182 0.72 
Hospital services 513.6 747.8 0 2,566.0 577.5 1,248.9 0 5,217.0 550.4 1,057.4 0 5,217.0 0.83 
Community services 575.5 1,108.9 0 4,355.3 682.4 1,010.9 0 3,061.6 637.2 1,044.2 0 4,355.3 0.72 
Equipment and 
adaptations 68.2 135.7 0 502.5 112.0 158.6 0 459.1 93.4 149.5 0 502.5 0.30 
Day services 270.2 550.0 0 2,055.6 259.6 492.5 0 1,778.9 264.1 512.3 0 2,055.6 0.94 
Medications 275.7 194.3 3 882.8 272.8 177.0 0 691.3 274.0 182.7 0 882.8 0.96 
Total HSC 2,654.8 3,756.8 315.7 16,121 3,205.1 3,595.1 129.4 13,747 2,972.3 3,638.2 129.4 16,121 0.61 
Unpaid care 6,563.3 4,953.9 0 15,366 7,812.1 6,273.3 0 24,870 7,283.8 5,733.3 0 24,870 0.42 
Total Societal 9,218.2 5,647.8 465.9 21,113 11,017 5,719.5 691.3 25,145 10,256 5,704.5 465.9 25,145 0.24 
Pre-baseline outcomes              
NPI 32.9 19.1 7.0 73.0 31.6 19.2 6.0 76.0 32.1 19.0 6.0 76.0 0.79 
ZBI 17.0 7.7 2.0 32.0 19.0 9.0 3.0 36.0 18.1 8.5 2.0 36.0 0.37 
DEMQOL 100.7 16.3 61.0 121.0 103.6 12.5 60.0 121.0 102.4 14.2 60.0 121.0 0.66 
Utility score (based on 
DEMQOL) 0.71 0.15 0.44 0.94 0.72 0.15 0.51 0.94 0.72 0.14 0.44 0.94 0.16 
GHQ 19.7 10.9 4.0 48.0 17.9 9.1 8.0 54.0 18.7 9.8 4.0 54.0 0.51 
Follow-up 12 weeks 
costs (£)              
Accommodation 632.7 2,967.7 0 13,919 697.0 2,361.4 0 10,468 669.8 2,607.4 0 13,919 0.80 
Hospital services 461.0 937.2 0 4,425.7 146.7 255.9 0 898.0 279.7 650.7 0 4,425.7 0.08 
Community services 270.4 707.0 0 3,229.0 390.5 782.2 0 3,919.9 339.7 746.5 0 3,919.9 0.65 
Equipment and 
adaptations 103.0 189.7 0 710.4 89.0 160.3 0 641.5 94.9 171.7 0 710.4 0.25 
Day services 270.5 519.5 0 1,937.0 229.1 476.8 0 1,541.7 246.6 490.7 0 1,937.0 0.78 
Medications 246.3 169.4 6 672.8 285.2 172.9 0 783.7 268.7 170.9 0 783.7 0.04 
Total HSC 1,983.8 3,080.5 85.7 14,528 1,837.5 2,511.8 118.4 11,367 1,899.4 2,738.7 85.7 14,528 0.41 
Intervention 0 0 0 0 284.0 43.2 190.0 320.0 163.8 145.4 0 320.0 - 
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Total HSC + 
intervention 1,983.8 3,080.5 85.7 14,528 2,121.5 2,509.7 417.5 11,627 2,063.2 2,737.5 85.7 14,528 0.76 
Unpaid care 5,820.7 6,750.9 0 28,626 8,411.6 5,727.0 0 24,570 7,315.5 6,251.9 0 28,626 0.24 
Total Societal + 
intervention 7,804.5 6,859.0 85.7 29,735 10,533 5,890.7 532.5 29,271 9,378.7 6,399.7 85.7 29,735 0.31 
Follow-up  12 weeks 
outcomes              
NPI 27.6 16.7 4.0 62.0 22.5 18.7 0.0 75.0 24.7 17.8 0.0 75.0 0.32 
ZBI 18.9 8.5 3.0 32.0 18.7 8.3 5.0 38.0 18.8 8.3 3.0 38.0 0.33 
DEMQOL 101.3 13.5 67.0 118.0 105.6 9.7 82.0 121.0 103.8 11.5 67.0 121.0 0.25 
Utility score (based on 
DEMQOL) 0.67 0.14 0.51 0.94 0.71 0.14 0.47 0.94 0.70 0.14 0.47 0.94 0.21 
GHQ 23.2 10.1 7.0 42.0 18.0 7.7 5.0 37.0 20.2 9.1 5.0 42.0 0.05 
 
Note: In relation to the outcome variables, for the control group, the sample size for ZBI was 21 at baseline and follow-up and 21 for GHQ only at follow-up, before the multiple imputation. 
For the intervention group, the original sample size for ZBI was 29 ad baseline and follow-up, and, only at follow-up, 29 for NPI and 28 for GHQ. In all the other cases, scores were recorded 
for the entirety of the economic subsample.  
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Table 4:  Incremental costs and effects (controlling for baseline costs and outcome)  
HSC perspective Incremental cost Incremental effect 
ICER 
 
(£, 2010/2011) Mean; [95% bootstrap CI] Mean; [95% bootstrap CI] 
0-12 weeks Mean Upper CI Lower CI  Mean Upper CI Lower CI  - 
NPI -168.6 -1,232.8 895.6 4.07 -4.65 12.79 Intervention dominant 
ZBI -170.8 -1,234.6 893.1 1.54 -1.78 4.86 Intervention dominant 
DEMQOL-Proxy -165.6 -1,251.7 920.6 2.87 -1.94 7.68 Intervention dominant 
QALY (DEMQOL-Proxy) -169.7 -1,240.0 900.5 0.0055 -0.0031 0.0140 Intervention dominant 
GHQ -173.6 -1,235.8 888.6 4.19 -0.55 8.93 Intervention dominant 
        Societal perspective Incremental cost Incremental effect
ICER 
 
(£, 2010/2011) Mean; [95% bootstrap CI] Mean; [95% bootstrap CI] 
0-12 weeks Mean Upper CI Lower CI  Mean Upper CI Lower CI    
NPI 1,686.4 -1,407.1 4,780.0 4.01 -4.72 12.73 421 
ZBI 1,641.1 -1,497.8 4,780.0 1.56 -1.75 4.86 1,055 
DEMQOL-Proxy 1,635.9 -1,520.9 4,792.6 2.82 -1.97 7.61 580 
QALY (DEMQOL-Proxy) 1,565.8 -1,592.6 4,724.2 0.0055 -0.0031 0.0140 286,440 
GHQ 1,657.3 -1,471.8 4,786.4 4.23 -0.50 8.97 392 
Note: Positive variations in the incremental effects represent improved outcomes. In order to obtain this, we reversed the scores for NPI, ZBI and GHQ. While dominance may be 
demonstrated, it must also be kept in mind that there were no significant differences in incremental costs and effects. 
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Table 5: Incremental costs and effects (controlling for socio-demographics, baseline costs and outcome)  
HSC perspective  Incremental cost Incremental effect 
ICER 
 
(£, 2010/2011) Mean; [95% bootstrap 
CI] Mean; [95% bootstrap CI] 
0-12 weeks Mean Upper CI Lower CI  Mean Upper CI Lower CI    
NPI -159.6 -1,267.8 948.5 2.46 -7.59 12.50 
Intervention 
dominant 
ZBI -155.9 -1,254.7 942.9 0.56 -3.90 5.02 
Intervention 
dominant 
DEMQOL-Proxy -156.5 -1,256.3 943.3 2.55 -3.32 8.41 
Intervention 
dominant 
QALY (DEMQOL-Proxy) -156.7 -1,257.4 944.1 0.0066 -0.0026 0.0157 
Intervention 
dominant 
GHQ -155.5 -1,250.6 939.5 4.00 -1.92 9.91 
Intervention 
dominant 
        Societal perspective Incremental cost Incremental effect 
ICER 
 
(£, 2010/2011) Mean; [95% bootstrap 
CI] Mean; [95% bootstrap CI] 
0-12 weeks Mean Upper CI Lower CI  Mean Upper CI Lower CI    
NPI 1,018.8 -2,331.0 4,368.7 2.42 -7.54 12.39 421 
ZBI 992.5 -2,384.6 4,369.6 0.58 -3.86 5.02 1,711 
DEMQOL-Proxy 978.1 -2,403.7 4,359.9 2.46 -3.40 8.33 397 
QALY (DEMQOL-Proxy) 954.0 -2,444.5 4,352.4 0.0065 -0.0025 0.0155 146,437 
GHQ 1,004.8 -2,349.2 4,358.8 4.07 -1.79 9.93 247 
Note: Positive variations in the incremental effects represent improved outcomes. While dominance may be demonstrated, it must also be kept in mind that there were no significant 
differences in incremental costs or effects. 
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Figure 1: Cost-effectiveness acceptability curves: exercise regimen vs. usual care; health and social care 
and societal perspectives; effectiveness measured on the NPI scale 
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